Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Chipscreen Bio Climbs 367% on First Trading Day following Shanghai IPO

publication date: Aug 12, 2019

China's Chipscreen Bio gained a stunning 367% in its first trading session following its IPO on the Shanghai STAR exchange, giving the company a market cap of $4.2 billion, When the first 25 STAR Board IPOs hit the market last month, the average gain was 140%, which was considered a huge jump. Chipscreen was 2.5 times larger. Chipscreen develops small molecule drugs for cancer, diabetes, endocrine and autoimmune diseases. It priced its IPO 27% above its original target and raised $148 million, an amount that now seems charmingly quaint. More details....

Stock Symbol: (SHA: 688321)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

ChinaBio Partnering Forum 2020

Content Availbalble Until Dec. 21, 2020